Latest news with #Topiramate
Business Standard
06-05-2025
- Business
- Business Standard
Senores Pharmaceuticals gains on acquiring Topiramate tablets from Wockhardt
Senores Pharmaceuticals added 1.53% to Rs 513.15 after it has signed an agreement with with Wockhardt to acquired USFDA-approved Topiramate HCl 25, 50, 100 and 200 mg tablets, used to treat epilepsy and migraine. Shares of Wockhardt declined 2.15% to Rs 1,267 on the BSE. The market size of Topiramate tablet in the USA was USD 111.47 million (MAT December 2024) as per IQVIA. The acquisition will be funded through the initial public offer (IPO) proceeds raised by SPL. This is in line with the objects of the IPO stated in the red herring prospectus. Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. Wockhardt is a research based global pharmaceutical and Biotech Company.
Business Standard
06-05-2025
- Business
- Business Standard
Stock Alert: Radico Khaitan, Coforge, CAMS, Senores Pharma, Indian Hotels
Securities in F&O Ban RBL Bank and Manappuram Finance shares are banned from F&O trading on Tuesday, 6 May 2025. Upcoming Results : Radico Khaitan, Godrej Consumer Products, Shipping Corp, Aadhar Housing Finance, Aarti Drugs, Alembic Pharmaceuticals, Aptus Value Housing Finance India, Avalon Technologies, Bank of Baroda, CG Power and Industrial Solutions, eMudhra, Hindustan Petroleum Corp., JBM Auto, Kajaria Ceramics, Kansai Nerolac Paints, KEI Industries, Vedant Fashions, Mahanagar Gas, Paradeep Phosphates, One 97 Communications, Piramal Enterprises, Polycab India will declare their result later today. Stocks to Watch: Computer Age Management Services (CAMS) reported a 10.2% jump in consolidated net profit to Rs 114.02 crore in Q4 FY25 as compared with Rs 103.50 crore in Q4 FY24. Net sales increased 14.7 % YoY to Rs 356.17 crore in Q4 FY25. Coforge reported a 20.81% jump in consolidated net profit from continuing operations to Rs 305.9 crore in Q4 FY25 as compared with Rs 253.2 crore in Q3 FY25. Revenue from operations increased 4.66% QoQ to Rs 3,409.9 crore in Q4 FY25. Indian Hotels consolidated net profit jumped 25% to Rs 522.30 crore in Q4 FY25 as compared with Rs 417.76 crore in Q4 FY24. Net sales increased 27.3% YoY to Rs 2425.14 crore in Q4 FY25. Cigniti Technologies consolidated net profit increased 15% to Rs 73 crore in Q4 FY25 as against Rs 63.57 crore in Q3 FY25. Net sales climbed 16.4% QoQ to Rs 530.28 crore in Q4 FY25. Senores Pharmaceuticals signed an agreement with with Wockhardt to acquire USFDA-approved Topiramate tablets, used to treat epilepsy and migraine. The market size of Topiramate Tablet in the US was $111.47 million. Ircon International received an order worth Rs 187 crore from Kerala State IT Infrastructure for the construction of a dedicated rural industrial park in Thiruvananthapuram.
Business Upturn
06-05-2025
- Business
- Business Upturn
Senores Pharmaceuticals share price jumps 3% after company acquires ANDA for Topiramate tablets from Wockhardt
By Aman Shukla Published on May 6, 2025, 09:28 IST Senores Pharmaceuticals' shares surged over 3% in early trading today after the company, through its wholly-owned U.S. subsidiary Senores Pharmaceuticals, Inc. (SPI), announced the acquisition of the Abbreviated New Drug Application (ANDA) for Topiramate Hydrochloride tablets from Wockhardt Limited. Topiramate, a generic medication, is commonly prescribed for the treatment of epilepsy and migraine. With the U.S. market for Topiramate tablets valued at approximately USD 111.47 million (IQVIA, MAT December 2024), the acquisition positions Senores Pharmaceuticals for substantial growth in the competitive generic drug market. The acquisition, which covers Topiramate Hydrochloride in strengths of 25 mg, 50 mg, 100 mg, and 200 mg, will be financed through the proceeds from the company's Initial Public Offering (IPO), in line with its objectives outlined in the Red Herring Prospectus. Senores Pharmaceuticals' stock opened at ₹510.00, reaching a high of ₹537.75 and a low of ₹510.00 during the trading session. The 52-week high for the stock stands at ₹665.00, while the 52-week low is ₹435.25. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
06-05-2025
- Business
- Time of India
Senores Pharma shares in focus after deal to acquire USFDA-approved epilepsy drug from Wockhardt
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Senores Pharmaceuticals are likely to be in focus on Tuesday after the company announced it is acquiring the USFDA-approved Abbreviated New Drug Application (ANDA) for Topiramate tablets from Wockhardt , expanding its U.S. product Pharmaceuticals Ltd (SPL), through its wholly owned subsidiary Senores Pharmaceuticals, Inc, USA (SPI), has signed an agreement to acquire the ANDA for Topiramate HCl 25, 50, 100, and 200 mg tablets. Topiramate is used in the treatment of epilepsy and migraine, with the US market valued at about USD 111.47 million as of December 2024, according to company said in a statement that the acquisition will be funded through proceeds from its December IPO, in line with the objectives outlined in its Red Herring made a strong stock market debut in December 2024, listing at a 53.45% premium at Rs 600 on the NSE and at Rs 593.7 on the BSE, a 51.8% jump over its upper price band of Rs then, however, shares have retreated, dropping 8% over the past three months, 5% in the last month, and 2% over the past stock is currently trading below all five key simple moving averages — the 5-day, 10-day, 20-day, 30-day, and 50-day SMAs. The 14-day Relative Strength Index (RSI) stands at 37.2, signaling the stock is approaching oversold levels but has yet to cross the typical 30 threshold.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Business Standard
05-05-2025
- Business
- Business Standard
Senores inks deal to acquire Wockhardt's ANDA for Topiramate
Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement today to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Topiramate HCl 25, 50, 100 and 200 mg tablets (Topiramate) from Wockhardt. Topiramate is indicated as a treatment of epilepsy and migraine. The market size of Topiramate Tablet in the USA was ~USD 111.47 Mn (MAT December 2024)1 as per IQVIA. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
